These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Emerging therapies in multiple myeloma. El-Amm J; Tabbara IA Am J Clin Oncol; 2015 Jun; 38(3):315-21. PubMed ID: 23934133 [TBL] [Abstract][Full Text] [Related]
4. Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease. Ashjian E; Redic K J Oncol Pharm Pract; 2016 Apr; 22(2):289-302. PubMed ID: 25694345 [TBL] [Abstract][Full Text] [Related]
5. Monoclonal Antibodies versus Histone Deacetylase Inhibitors in Combination with Bortezomib or Lenalidomide plus Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma: An Indirect-Comparison Meta-Analysis of Randomized Controlled Trials. Zheng Y; Shen H; Xu L; Feng J; Tang H; Zhang N; Chen X; Gao G J Immunol Res; 2018; 2018():7646913. PubMed ID: 30050957 [TBL] [Abstract][Full Text] [Related]
6. Pomalidomide in the treatment of relapsed multiple myeloma. Forsberg PA; Mark TM Future Oncol; 2013 Jul; 9(7):939-48. PubMed ID: 23837756 [TBL] [Abstract][Full Text] [Related]
10. [Treatment strategy for relapsed or refractory myeloma according to the new Guidelines]. Ozaki S Rinsho Ketsueki; 2018; 59(10):2178-2188. PubMed ID: 30305524 [TBL] [Abstract][Full Text] [Related]
11. Treatment of Relapsed/Refractory Multiple Myeloma. Neri P; Bahlis NJ; Paba-Prada C; Richardson P Cancer Treat Res; 2016; 169():169-194. PubMed ID: 27696263 [TBL] [Abstract][Full Text] [Related]
12. How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients? Sonneveld P; De Wit E; Moreau P Crit Rev Oncol Hematol; 2017 Apr; 112():153-170. PubMed ID: 28325256 [TBL] [Abstract][Full Text] [Related]
13. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies. Morgan G Blood Rev; 2010 Nov; 24 Suppl 1():S27-32. PubMed ID: 21126634 [TBL] [Abstract][Full Text] [Related]
14. Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma. Jagannath S; Dimopoulos MA; Lonial S Leuk Res; 2010 Sep; 34(9):1111-8. PubMed ID: 20472288 [TBL] [Abstract][Full Text] [Related]
15. Novel therapies for relapsed myeloma. Stewart AK Hematology Am Soc Hematol Educ Program; 2009; ():578-86. PubMed ID: 20008242 [TBL] [Abstract][Full Text] [Related]
17. [New drugs in the treatment of multiple myeloma]. Oriol A; Motlló C Med Clin (Barc); 2014 Sep; 143(6):268-74. PubMed ID: 24342015 [TBL] [Abstract][Full Text] [Related]
18. Novel drug combinations for the management of relapsed/refractory multiple myeloma. Usmani SZ; Lonial S Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S71-7. PubMed ID: 25486960 [TBL] [Abstract][Full Text] [Related]
19. New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients. van de Donk NW; Lokhorst HM Expert Opin Pharmacother; 2013 Aug; 14(12):1569-73. PubMed ID: 23721099 [TBL] [Abstract][Full Text] [Related]
20. A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma. Cook G; Zweegman S; Mateos MV; Suzan F; Moreau P Crit Rev Oncol Hematol; 2018 Jan; 121():74-89. PubMed ID: 29279102 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]